{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rosacea/management/rosacea/","result":{"pageContext":{"chapter":{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea","depth":2,"htmlHeader":"<!-- begin field 0b249287-1803-48d0-acc8-0db2c562d9a1 --><h2>Scenario: Rosacea</h2><!-- end field 0b249287-1803-48d0-acc8-0db2c562d9a1 -->","summary":"Covers the management of rosacea in primary care.","htmlStringContent":"<!-- begin item 7d89a36a-cd21-4b04-9559-6c2e5f170672 --><!-- begin field 744a3166-a2ab-4025-b67b-acbc015c18b4 --><p>From age 16 years onwards.</p><!-- end field 744a3166-a2ab-4025-b67b-acbc015c18b4 --><!-- end item 7d89a36a-cd21-4b04-9559-6c2e5f170672 -->","topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","lastRevised":"Last revised in January 2021","chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","fullItemName":"Management","slug":"management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"fa705c3a-7dc9-55a6-b1b9-a8e136293975","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field f7f58c6c-6e81-4390-a00c-f5345f174ecf --><h3>How should I manage a person with rosacea?</h3><!-- end field f7f58c6c-6e81-4390-a00c-f5345f174ecf -->","summary":null,"htmlStringContent":"<!-- begin item 11820a60-4185-45ca-95ee-611b8cc462da --><!-- begin field 27440ec9-8e71-49bc-a300-da85334c60ef --><p><strong>If a person has a <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/diagnosis/diagnosis/\">suspected</a> diagnosis of rosacea, management should be based on the presenting <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/diagnosis/diagnosis/\">clinical phenotype</a>, and may involve more than one treatment.</strong></p><ul><li><strong>Advise that:</strong><ul><li>Rosacea is a chronic condition that may improve with treatment, but intermittent relapses may occur.</li><li>The aim of treatment should be complete skin clearance, where possible.</li></ul></li><li><strong>Provide advice on sources of information and support,</strong> such as:<ul><li>The British Skin Foundation (website available at <a data-hyperlink-id=\"6789a7c6-81d3-4ef8-85e7-abd601409633\" href=\"https://www.britishskinfoundation.org.uk/\" rel=\"noopener\" target=\"_blank\">www.britishskinfoundation.org.uk</a>) is a national charity that aims to raise awareness of skin conditions, provide education, and reduce stigma.</li><li>The British Association of Dermatologists patient leaflets <a data-hyperlink-id=\"50dda59a-0d1f-41aa-8d03-abd601409661\" href=\"https://www.skinhealthinfo.org.uk/wp-content/uploads/2018/11/Rosacea-Update-August-2018-Lay-review-June-2018.pdf\" rel=\"noopener\" target=\"_blank\">Rosacea</a> and <a data-hyperlink-id=\"18aeb12a-5c5a-4bc6-a6b7-abd601409672\" href=\"https://www.skinhealthinfo.org.uk/wp-content/uploads/2018/11/Rhinophyma-Update-February-2018-Lay-reviewed-Janauary-2018.pdf\" rel=\"noopener\" target=\"_blank\">Rhinophyma</a> may be helpful.</li><li>The NHS information leaflet <a data-hyperlink-id=\"0019f235-d915-4aed-87b1-abd60140967e\" href=\"https://www.nhs.uk/conditions/rosacea/\" rel=\"noopener\" target=\"_blank\">Rosacea</a> may be helpful.</li><li>The patient.info leaflet <a data-hyperlink-id=\"0a82793d-08a3-4be1-875a-abd601409696\" href=\"https://patient.info/skin-conditions/skin-rashes/rosacea\" rel=\"noopener\" target=\"_blank\">Rosacea</a> may be helpful.</li></ul></li><li><strong>Provide advice on self-management measures:</strong><ul><li>Advise on the importance of avoiding <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/background-information/risk-factors/\">trigger factors</a> wherever possible.<ul><li>Suggest that a diary may be helpful to identify stimuli and triggers that may exacerbate rosacea.</li></ul></li><li>Advise on the importance of effective sun protection and to avoid the use of sunbeds.<ul><li>High-factor sunscreen with protection against ultraviolet A and B (for example Uvistat<sup>®</sup> or Sunsense<sup>®</sup>) can be prescribed (these are classified as 'borderline substances' and the prescription must be endorsed 'ACBS').</li><li>Ultraviolet protection sunglasses may be helpful for people with features of <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/diagnosis/diagnosis/\">ocular rosacea</a>.</li></ul></li><li>Advise on general skincare measures such as:<ul><li>The use of regular non-oily emollients if the skin is dry. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a> for detailed prescribing information on emollients.</li><li>The use of gentle soap-free over-the-counter cleansers.</li><li>The possible use of yellow- or green-tinted cosmetics to help camouflage skin erythema.</li></ul></li></ul></li><li><strong>Offer referral to a skin camouflage service,</strong> if appropriate. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/management/rosacea/#referral\">Referral</a> for more information.</li><li><strong>Manage any associated psychosocial co-morbidities.</strong> See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.</li><li><strong>Prescribe first-line topical and/or oral drug treatments, depending on the clinical phenotype and severity of disease, and the person's preferences.</strong><ul><li>If there is persistent erythema, consider prescribing topical brimonidine 0.5% gel (a topical alpha-adrenergic agonist) once daily on an 'as needed' basis, for temporary relief of symptoms, depending on local prescribing guidelines. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/topical-treatments/#brimonidine\">Brimonidine</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/\">Prescribing information</a> for more information, including contraindications and cautions.<ul><li>Advise that topical brimonidine may reduce erythema within 30 minutes, reaching peak action at 3–6 hours, after which the effect diminishes and erythema returns to baseline.</li><li>Advise that telangiectasia may be accentuated as general erythema is reduced.</li></ul></li><li>If there are mild-to-moderate papules and/or pustules, prescribe topical ivermectin (an antihelmintic and insecticidal preparation) once daily for 8–12 weeks, depending on local prescribing guidelines. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/topical-treatments/#ivermectin\">Ivermectin</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/\">Prescribing information</a> for more information, including contraindications and cautions.<ul><li>Alternative topical preparations are metronidazole 0.75% applied twice daily or azelaic acid 15% applied twice daily, if ivermectin is not available or inappropriate, for example for pregnant or breastfeeding women. See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/topical-treatments/#metronidazole\">Metronidazole</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/topical-treatments/#azelaic-acid\">Azelaic acid</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>If there are moderate-to-severe papules and/or pustules, prescribe a combination of topical ivermectin, depending on local prescribing guidelines, together with oral doxycycline 40 mg once daily as a modified-release preparation for 8–12 weeks. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/oral-antibiotics/#doxycycline\">Doxycycline</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Alternative topical preparations are metronidazole 0.75% applied twice daily or azelaic acid 15% applied twice daily, if ivermectin is not available or inappropriate, for example for pregnant or breastfeeding women.</li><li>Alternative oral preparations are oxytetracycline 500 mg twice daily or tetracycline 500 mg twice daily, or erythromycin 500 mg twice daily for pregnant or breastfeeding women. See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/oral-antibiotics/#oxytetracycline\">Oxytetracycline</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/oral-antibiotics/#tetracycline\">Tetracycline</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/prescribing-information/oral-antibiotics/#erythromycin\">Erythromycin</a> for more information.</li></ul></li><li>If there is clinically inflamed phymatous disease, consider prescribing oral doxycycline 40 mg once daily as a modified-release preparation (off-label indication) for 6 weeks.</li><li>If there is suspected <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/diagnosis/diagnosis/\">ocular rosacea</a>, manage appropriately and advise on:<ul><li>Lid hygiene measures. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/blepharitis/\">Blepharitis</a> for more information.</li><li>The use of artificial tears or ocular lubricants (for mild ocular burning and stinging symptoms and dry eyes). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dry-eye-syndrome/\">Dry eye syndrome</a> for more information.</li></ul></li></ul></li><li><strong>Arrange to review the person following first-line treatment(s), to assess the clinical response, need for maintenance therapy, alternative treatment, or referral.</strong><ul><li>For mild-to-moderate papules and/or pustules, if there is a clinical improvement:<ul><li>Continue maintenance treatment with topical preparations as needed, ideally until the skin is clear.</li></ul></li><li>For mild-to-moderate papules and/or pustules, if there is little or no improvement, consider prescribing a combination of topical preparation together with oral doxycycline 40 mg once daily as a modified-release preparation for 8–12 weeks.<ul><li>Alternative oral preparations are oxytetracycline or tetracycline 500 mg twice daily, or erythromycin 500 mg twice daily for pregnant or breastfeeding women.</li></ul></li><li>For moderate-to-severe papules and/or pustules, if there is a clinical improvement:<ul><li>Continue combination treatment up to 12–16 weeks, then reassess the need for ongoing oral antibiotic treatment and continue topical treatment, depending on clinical judgement.</li></ul></li><li>For moderate-to-severe papules and/or pustules if there is little or no improvement, consider arranging referral to dermatology, depending on clinical judgement. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/management/rosacea/#referral\">Referral</a> for more information.</li><li>For suspected ocular rosacea following 2–4 weeks of self-care treatment:<ul><li>If there is a clinical improvement, continue management as needed.</li><li>If there is little or no improvement, considering arranging referral to ophthalmology, depending on clinical judgement. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/management/rosacea/#referral\">Referral</a> for more information.</li></ul></li></ul></li></ul><!-- end field 27440ec9-8e71-49bc-a300-da85334c60ef --><!-- end item 11820a60-4185-45ca-95ee-611b8cc462da -->","subChapters":[{"id":"7c243ab1-b45e-50cc-9299-1d05151c3466","slug":"basis-for-recommendation-16f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 295dc707-0020-401e-ae53-498e50c203ae --><h4>Basis for recommendation</h4><!-- end field 295dc707-0020-401e-ae53-498e50c203ae -->","summary":null,"htmlStringContent":"<!-- begin item 16f9d8d8-e5a8-4953-b241-f0fde7174f90 --><!-- begin field 18e3e382-6dd8-46dd-a324-37a489f260b4 --><p>The recommendations on management are largely based on the ROSacea COnsensus (ROSCO) international consensus publications <em>Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and <em>Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>]; the US National Rosacea Society (NRS) expert committee publication <em>Standard classification and pathophysiology of rosacea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>]; a Dutch clinical guideline <em>Rosacea treatment guideline for the Netherlands</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>]; the College of Optometrists clinical management guideline <em>Ocular rosacea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>]; two National Institute for Health and Care Excellence (NICE) evidence summaries on brimonidine gel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">NICE, 2014</a>] and on ivermectin cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">NICE, 2016</a>]; a systematic review of interventions for rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2019</a>]; and expert opinion in review articles on rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>] and on the phenotype approach to classification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2018</a>].</p><h5>Providing an individualized approach to management</h5><ul><li>The ROSCO update publication notes that the unique nature of each person's rosacea phenotype and personal circumstances demands an individualized treatment and management strategy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>]. This approach is supported by expert opinion in a review article, which notes that disease management should be based on the presenting clinical features and may involve more than one treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].</li><li>The ROSCO consensus publication on treatment notes that multiple cutaneous features of rosacea can be treated with more than one agent simultaneously [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>]. Similarly, expert opinion in a review article states that the phenotype approach to rosacea classification allows the use of combination therapy when needed, to manage multiple presenting features and optimize clinical outcomes and quality of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2018</a>].</li><li>The information that rosacea may relapse intermittently is based on the NRS expert committee publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>].</li><li>The recommendation to aim for complete skin clearance where possible is based on the ROSCO consensus update, which states this approach will minimize impact on quality of life, delay time to disease relapse, and maximize patient satisfaction from treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>].</li></ul><h5>Advising on sources of information and support</h5><ul><li>The recommendation to provide information about rosacea is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Advising on self-management measures</h5><ul><li>The recommendation to advise trigger avoidance is based on the ROSCO consensus publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], the College of Optometrists clinical management guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].<ul><li>A diary may be helpful to identify stimuli and triggers that may exacerbate rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].</li></ul></li><li>The recommendation on effective sun protection is based on the ROSCO consensus publication on treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and the Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].<ul><li>The information on the prescription of high-factor sunscreen as a 'borderline substance' is based on expert opinion in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>].</li><li>The information on the use of ultraviolet‐coated sunglasses for people with ocular features is based on the ROSCO consensus publication on treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>].</li></ul></li><li>The recommendations on general skincare measures, including use of emollients and cleansers, are based on the ROSCO consensus publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], the Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].<ul><li>General skincare is the main management strategy for the secondary features of rosacea, which include dry appearance, dry sensation, and stinging sensation of the skin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>].</li><li>Properly selected skincare products improve and maintain the integrity of the stratum corneum permeability barrier and reduce skin sensitivity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>].</li></ul></li><li>The recommendation to consider the use of tinted cosmetics to camouflage skin erythema is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>].</li></ul><h5>Offering referral to a skin camouflage service</h5><ul><li>This recommendation is extrapolated from the ROSCO update publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], and is also pragmatic, based on what CKS considers to be good clinical practice. It is also in line with the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Managing associated psychosocial co-morbidities</h5><ul><li>This recommendation is based on the NRS expert committee publication, which highlights the potential adverse impact of rosacea on a person's emotional, social, and occupational wellbeing, including its link to severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>]. This approach is supported by the ROSCO update publication that notes that the psychosocial impact is often poorly correlated with clinical severity of disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], and the Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].</li></ul><h5>Prescribing first-line topical and/or oral drug treatments</h5><ul><li>The recommendations on first-line drug treatments are largely based on a Dutch clinical guideline, whose working group made recommendations depending on the level of available evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>]. It based its approach on a systematic review of 152 randomized controlled trials (RCTs; n = 20,944) of treatments for rosacea using a phenotype approach. This found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2019</a>]:<ul><li>No evidence from RCTs on the treatment of transient erythema and flushing.</li><li>Good quality evidence for the efficacy and safety of topical brimonidine for the transient reduction of persistent erythema, due to its transient vasoconstriction of cutaneous superficial blood vessels. There was moderate-quality evidence of little to no difference in the number of trial participants experiencing an adverse event when compared with vehicle.</li><li>High-certainty evidence for the use of topical azelaic acid and topical ivermectin for reducing papule and/or pustule lesion counts; moderate-to-high-certainty evidence for the use of low-dose modified-release doxycycline; and moderate-certainty evidence for the use of topical metronidazole. Topical azelaic acid was noted to have a higher incidence of adverse effects, such as skin burning, stinging, or irritation. There was low-certainty evidence that low-dose modified-release doxycycline is at least as effective as the higher-dose 100 mg preparation, with fewer adverse effects noted.</li><li>Regarding alternative oral preparations to doxycycline, low-certainty evidence that tetracycline is effective for reducing papules and/or pustules. There was moderate-certainty evidence of probably little to no difference between oral minocycline and low-dose modified-release doxycycline, however, there was an increased risk of adverse effects with oral minocycline, such as autoimmune hepatitis, lupus erythematosus, and hyperpigmentation of the skin.</li><li>Overall, for most treatments or treatment combinations, no clear evidence favouring any treatment regarding higher remission rates or fewer adverse events. Two RCTs showed evidence that combining treatments had a beneficial effect on more than one phenotype clinical feature of rosacea. The authors noted, however, the lack of standardized and validated scales was challenging for pooling data from different studies.</li></ul></li><li>The recommendation on the use of topical brimonidine is also based on the NICE evidence summary on brimonidine gel, which cites two short-term RCTs that found it was significantly more effective than vehicle in reducing erythema in people with rosacea, and was generally well tolerated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">NICE, 2014</a>].<ul><li>CKS notes that the use of topical brimonidine may be restricted, depending on local prescribing guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>].</li></ul></li><li>The recommendation on the use of topical ivermectin is also based on the NICE evidence summary on ivermectin cream, which notes it has antihelmintic and insecticidal properties, which may be relevant for the eradication of <em>Demodex folliculorum</em> mites, which are implicated in the pathogenesis of rosacea. The review was largely based on two RCTs comparing ivermectin cream with vehicle, and a RCT comparing ivermectin cream with metronidazole 0.75% cream, together with long-term safety trials and a public assessment report [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">NICE, 2016</a>].<ul><li>CKS notes that the use of topical ivermectin may be restricted, depending on local prescribing guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>].</li></ul></li><li>The recommendations on alternative treatments and treatment duration are largely based on the Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>] and expert opinion in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>].<ul><li>CKS notes that the Dutch clinical guideline does not give a duration of treatment for clinically inflamed phymatous disease with oral antibiotics. CKS has therefore extrapolated its recommendation from expert opinion in the BNF on the treatment of papules and/or pustules, which recommends low-dose modified-release doxycycline for 6 weeks initially, and to discontinue treatment after this time if there is no clinical response.</li><li>The recommendation on the alternative use of oral tetracycline or oxytetracycline if oral doxycycline is not tolerated or is contraindicated is extrapolated from the ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendation on the alternative use of erythromycin if tetracyclines are not tolerated or are contraindicated (such as for pregnant or breastfeeding women) is extrapolated from expert opinion in a review article, which notes that azithromycin, clarithromycin, or erythromycin may be considered, based on mainly observational studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>]. It is also based on expert opinion in the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>] and is pragmatic, based on what CKS considers to be good clinical practice.</li></ul></li><li>The recommendations on the initial management of suspected ocular rosacea are based on the College of Optometrists clinical management guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>]. They are supported by the ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and a Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].<ul><li>The College of Optometrists guideline advises on the management of associated conditions, such as chalazion, hordeolum (stye), posterior blepharitis, and dry eye.</li></ul></li></ul><h5>Arranging review to assess clinical response</h5><ul><li>The ROSCO consensus publication highlights the importance of ensuring treatments are used for a sufficient duration before switching to an alternative, and the need to adjust or combine treatments depending on the person's rosacea phenotype and response to therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>]. In addition, the ROSCO consensus update recommends assessing the need for maintenance therapy, monitoring changes in disease features, their impact, and the response to treatment, including tolerability and efficacy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>].</li><li>The recommendations on maintenance therapy or stepping up therapy for rosacea with papules and/or pustules is largely based on the Dutch clinical guideline. It noted three RCTs that found topical metronidazole, topical ivermectin, and topical azelaic acid seemed effective and safe as maintenance therapy for this rosacea phenotype [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].</li><li>The recommendation on arranging dermatology referral is based on the fact non-responsive disease may require specialist treatment, such as a trial of oral isotretinoin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].</li><li>The recommendation on the management of ocular rosacea if there is no improvement after 2–4 weeks of self-care measures, is based on the Dutch clinical guideline, which recommends referral to ophthalmology for possible ciclosporin ophthalmic emulsion or oral antibiotic treatment, such as doxycycline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].</li></ul><!-- end field 18e3e382-6dd8-46dd-a324-37a489f260b4 --><!-- end item 16f9d8d8-e5a8-4953-b241-f0fde7174f90 -->","subChapters":[]}]},{"id":"cf28dd65-75e7-5276-996f-6b644d544287","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field d499dbd0-3461-46f6-a0a5-5ca584040682 --><h3>When should I refer a person with rosacea?</h3><!-- end field d499dbd0-3461-46f6-a0a5-5ca584040682 -->","summary":null,"htmlStringContent":"<!-- begin item 397a8da3-c4fe-4fcb-ad5f-3802e8c4734b --><!-- begin field ee11e300-014c-4a5e-83dd-6994754a7215 --><p><strong>If a person with <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/diagnosis/diagnosis/\">suspected</a> rosacea has persistent or severe symptoms:</strong></p><ul><li><strong>Consider arranging referral to a dermatologist for possible <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/management/rosacea/#specialist-management\">specialist management</a> if there is:</strong><ul><li>Persistent erythema that has not responded to <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/management/rosacea/#management\">optimal management</a> in primary care.</li><li>Persistent inflammatory papules and/or pustules that have not responded to <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/management/rosacea/#management\">optimal management</a> in primary care.</li><li>Severe telangiectasia that have not responded to self-management advice, depending on clinical judgement and local referral guidelines.</li><li>An uncertain diagnosis.</li></ul></li><li><strong>Consider arranging referral to a local skin camouflage service</strong> (which may be available through the local dermatology service).<ul><li>Advise that people may self-refer to the charity Changing Faces, which provides education from skin camouflage practitioners on the use and application of cosmetic camouflage creams and powders. The website (available at <a data-hyperlink-id=\"fecdf26f-c40a-4d9a-a561-abe201075fdf\" href=\"https://www.changingfaces.org.uk/\" rel=\"noopener\" target=\"_blank\">www.changingfaces.org.uk</a>) provides patient information on <a data-hyperlink-id=\"64376745-adb3-48ee-b242-abe201075fe9\" href=\"https://www.changingfaces.org.uk/skin-camouflage\" rel=\"noopener\" target=\"_blank\">Skin camouflage</a>, details of local skin camouflage services, a telephone helpline, and online support forum.</li></ul></li><li><strong>Consider arranging referral to a plastic surgeon if there is:</strong><ul><li>Prominent non-inflamed phymatous disease.</li></ul></li><li><strong>Arrange referral to an ophthalmologist, the urgency depending on clinical judgement, if:</strong><ul><li>A serious eye complication, such as keratitis or anterior uveitis, is suspected (for example suggested by sudden pain, red eye, and/or visual disturbance). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/red-eye/\">Red eye</a> and <a class=\"topic-reference external-reference\" href=\"/topics/uveitis/\">Uveitis</a> for more information.</li><li>Other associated <a class=\"topic-reference internal-reference\" href=\"/topics/rosacea/diagnosis/diagnosis/\">ocular symptoms</a> are severe or do not respond to optimal management in primary care. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/blepharitis/\">Blepharitis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/meibomian-cyst-chalazion/\">Meibomian cyst (chalazion)</a>, <a class=\"topic-reference external-reference\" href=\"/topics/styes-hordeola/\">Styes (hordeola)</a>, <a class=\"topic-reference external-reference\" href=\"/topics/conjunctivitis-infective/\">Conjunctivitis</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/dry-eye-syndrome/\">Dry eye syndrome</a> for more information.</li></ul></li></ul><!-- end field ee11e300-014c-4a5e-83dd-6994754a7215 --><!-- end item 397a8da3-c4fe-4fcb-ad5f-3802e8c4734b -->","subChapters":[{"id":"0137cb2a-3b75-596d-a2e3-f2472ff00178","slug":"specialist-management","fullItemName":"Specialist management","depth":4,"htmlHeader":"<!-- begin field 91017f76-5308-43be-959c-248edb2d6263 --><h4>Specialist management</h4><!-- end field 91017f76-5308-43be-959c-248edb2d6263 -->","summary":null,"htmlStringContent":"<!-- begin item 19742a23-6df8-4b04-8cbd-1a7e50cf5431 --><!-- begin field 940d3f93-1200-4ba5-bd3c-f2122fb933bc --><p><strong>S</strong><strong>pecialist treatment options may include:</strong></p><ul><li>Oral isotretinoin for severe inflammatory papules and/or pustules, or clinically inflamed phymatous disease.</li><li>Electrodessication, intense pulsed light (IPL) therapy, or pulsed dye/Nd:YAG laser therapy for persistent erythema and/or telangiectasia.</li><li>Topical alpha-adrenergic modulating agents, such as brimonidine for flushing or transient erythema, in specific situations.</li><li>Laser therapy or non-laser physical modalities, such as electrosurgery, microdermabrasion, excision, loop cautery, or scissor sculpting, for clinically non-inflamed severe phymatous disease.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Oge, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Del Rosso, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>]</p><!-- end field 940d3f93-1200-4ba5-bd3c-f2122fb933bc --><!-- end item 19742a23-6df8-4b04-8cbd-1a7e50cf5431 -->","subChapters":[]},{"id":"e9576a4e-5b6b-5400-9821-7eb93b629b31","slug":"basis-for-recommendation-5a4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0dd77247-87df-4ba3-bf35-5b79038858ae --><h4>Basis for recommendation</h4><!-- end field 0dd77247-87df-4ba3-bf35-5b79038858ae -->","summary":null,"htmlStringContent":"<!-- begin item 5a4a73a9-1747-4505-8fd6-dd14831e1da7 --><!-- begin field 93c5ff02-bcb3-4a8a-a95b-762e0b7c4240 --><p>The recommendations on referral are largely based on the ROSacea COnsensus (ROSCO) international consensus publications <em>Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>], <em>Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>], and <em>Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>]; the US National Rosacea Society (NRS) expert committee publication <em>Standard classification and pathophysiology of rosacea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>]; a Dutch clinical guideline <em>Rosacea treatment guideline for the Netherlands</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>]; the College of Optometrists clinical management guideline <em>Ocular rosacea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>]; and expert opinion in a review article on rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>] and on the global epidemiology of rosacea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Alexis, 2019</a>].</p><h5>Arranging referral to dermatology</h5><ul><li>These recommendations are extrapolated from a Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>], the ROSCO consensus publications on treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and on diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Tan, 2017</a>], the NRS expert committee publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Alexis, 2019</a>].<ul><li>The Dutch clinical guideline notes that if a person has severe papules and/or pustules that have not responded to combination therapy in primary care including oral tetracyclines, they may be offered specialist treatment with oral isotretinoin.</li><li>The ROSCO consensus publication on diagnosis notes that skin biopsy may be needed if there is an uncertain diagnosis, for example in people with darker skin phototypes, where diagnostic features of erythema and telangiectasia may be difficult to detect. Similarly, the NRS publication and expert opinion in a review article state that use of a dermatoscope may allow for detection of telangiectasia in people with darker skin types [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Gallo, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Alexis, 2019</a>].</li></ul></li></ul><h5>Arranging referral to a skin camouflage service</h5><ul><li>This recommendation is pragmatic, based on what CKS considers to be good clinical practice. It is also in line with the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Arranging referral to plastic surgery</h5><ul><li>This recommendation is extrapolated from the ROSCO consensus publication on treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2017</a>] and the Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>].</li></ul><h5>Arranging referral to ophthalmology</h5><ul><li>These recommendations are based on the College of Optometrists clinical management guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">College of Optometrists, 2018</a>], the ROSCO consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Schaller, 2020</a>], the Dutch clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2020</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].<ul><li>The College of Optometrists guideline mentions possible management by an ophthalmologist includes topical ciclosporin (off-label indication), topical corticosteroid for severe corneal disease, topical ivermectin for eyelid skin involvement, and possible surgery for corneal disease.</li><li>Expert opinion in a review article notes that specialist referral is appropriate if symptoms persist despite primary care management if other diagnoses need to be ruled out and to prevent rare complications, such as sight-threatening keratitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">van Zuuren, 2017</a>].</li></ul></li></ul><!-- end field 93c5ff02-bcb3-4a8a-a95b-762e0b7c4240 --><!-- end item 5a4a73a9-1747-4505-8fd6-dd14831e1da7 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}